Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Kristoff Muylle; P. Flamen; DJ Vugts; T Guiot; G Ghanem; N Meuleman; P Bourgeois; B Vanderlinden; GAMS van Dongen; Hendrik Everaert; M Vaes; D Bron

Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Kristoff Muylle, P. Flamen, DJ Vugts, T Guiot, G Ghanem, N Meuleman, P Bourgeois, B Vanderlinden, GAMS van Dongen, Hendrik Everaert, M Vaes, D Bron

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1304-1314
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	42
Publication status	Published - 2015

Cite this

Muylle, K., Flamen, P., Vugts, DJ., Guiot, T., Ghanem, G., Meuleman, N., Bourgeois, P., Vanderlinden, B., van Dongen, GAMS., Everaert, H., Vaes, M., & Bron, D. (2015). Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. European Journal of Nuclear Medicine and Molecular Imaging, 42, 1304-1314.

Muylle, Kristoff ; Flamen, P. ; Vugts, DJ ; Guiot, T ; Ghanem, G ; Meuleman, N ; Bourgeois, P ; Vanderlinden, B ; van Dongen, GAMS ; Everaert, Hendrik ; Vaes, M ; Bron, D. / Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. In: European Journal of Nuclear Medicine and Molecular Imaging. 2015 ; Vol. 42. pp. 1304-1314.

@article{bdef26d67fc04251bc5da37934fd6ca9,

title = "Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.",

author = "Kristoff Muylle and P. Flamen and DJ Vugts and T Guiot and G Ghanem and N Meuleman and P Bourgeois and B Vanderlinden and {van Dongen}, GAMS and Hendrik Everaert and M Vaes and D Bron",

year = "2015",

language = "English",

volume = "42",

pages = "1304--1314",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

}

Muylle, K, Flamen, P, Vugts, DJ, Guiot, T, Ghanem, G, Meuleman, N, Bourgeois, P, Vanderlinden, B, van Dongen, GAMS, Everaert, H, Vaes, M & Bron, D 2015, 'Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.', European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, pp. 1304-1314.

Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. / Muylle, Kristoff; Flamen, P.; Vugts, DJ; Guiot, T; Ghanem, G; Meuleman, N; Bourgeois, P; Vanderlinden, B; van Dongen, GAMS; Everaert, Hendrik; Vaes, M; Bron, D.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, 2015, p. 1304-1314.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Tumour targeting and radiation dose of radioimmunotherapy with 90Y-rituximab in CD20+ B-cell lymphoma as predicted by 89Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

AU - Muylle, Kristoff

AU - Flamen, P.

AU - Vugts, DJ

AU - Guiot, T

AU - Ghanem, G

AU - Meuleman, N

AU - Bourgeois, P

AU - Vanderlinden, B

AU - van Dongen, GAMS

AU - Everaert, Hendrik

AU - Vaes, M

AU - Bron, D

PY - 2015

Y1 - 2015

M3 - Article

VL - 42

SP - 1304

EP - 1314

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -